Frost & Sullivan Independent Equity Research

RedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59


Company: RedHill Biopharma        

Sector: Pharmaceuticals

Report type: Q1-2018 Update Report and 12 months since Initiation

Published on: 22 May, 2018

RedHill research articles: